# | Title | Journal | Year | Citations |
---|
1 | Cognitive behavior therapy via the Internet: a systematic review of applications, clinical efficacy and cost–effectiveness | Expert Review of Pharmacoeconomics and Outcomes Research | 2012 | 556 |
2 | KIDSCREEN-52 quality-of-life measure for children and adolescents | Expert Review of Pharmacoeconomics and Outcomes Research | 2005 | 551 |
3 | Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold | Expert Review of Pharmacoeconomics and Outcomes Research | 2008 | 543 |
4 | A point of minimal important difference (MID): a critique of terminology and methods | Expert Review of Pharmacoeconomics and Outcomes Research | 2011 | 465 |
5 | The truly remarkable universality of half a standard deviation: confirmation through another look | Expert Review of Pharmacoeconomics and Outcomes Research | 2004 | 375 |
6 | Impact of multidrug-resistantPseudomonas aeruginosainfection on patient outcomes | Expert Review of Pharmacoeconomics and Outcomes Research | 2010 | 336 |
7 | Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research | Expert Review of Pharmacoeconomics and Outcomes Research | 2010 | 325 |
8 | Economic burden of healthcare-associated infections: an American perspective | Expert Review of Pharmacoeconomics and Outcomes Research | 2009 | 260 |
9 | Globalization and healthcare: understanding health and medical tourism | Expert Review of Pharmacoeconomics and Outcomes Research | 2006 | 247 |
10 | Interpreting patient-reported outcome results: US FDA guidance and emerging methods | Expert Review of Pharmacoeconomics and Outcomes Research | 2011 | 242 |
11 | Internet-delivered treatments with or without therapist input: does the therapist factor have implications for efficacy and cost? | Expert Review of Pharmacoeconomics and Outcomes Research | 2007 | 238 |
12 | The PedsQL™ as a pediatric patient-reported outcome: reliability and validity of the PedsQL™ Measurement Model in 25,000 children | Expert Review of Pharmacoeconomics and Outcomes Research | 2005 | 232 |
13 | The minimum clinically important difference for EQ-5D index: a critical review | Expert Review of Pharmacoeconomics and Outcomes Research | 2014 | 217 |
14 | Valuing citizen and patient preferences in health: recent developments in three types of best–worst scaling | Expert Review of Pharmacoeconomics and Outcomes Research | 2010 | 197 |
15 | Rating scales and Rasch measurement | Expert Review of Pharmacoeconomics and Outcomes Research | 2011 | 185 |
16 | Patient recall and recall bias of health state and health status | Expert Review of Pharmacoeconomics and Outcomes Research | 2004 | 183 |
17 | Discrete choice experiments to measure consumer preferences for health and healthcare | Expert Review of Pharmacoeconomics and Outcomes Research | 2002 | 175 |
18 | Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy | Expert Review of Pharmacoeconomics and Outcomes Research | 2020 | 151 |
19 | Premenstrual syndrome and premenstrual dysphoric disorder: quality of life and burden of illness | Expert Review of Pharmacoeconomics and Outcomes Research | 2009 | 147 |
20 | Half standard deviation estimate of the minimally important difference in HRQOL scores? | Expert Review of Pharmacoeconomics and Outcomes Research | 2004 | 143 |
21 | PRODISQ: a modular questionnaire on productivity and disease for economic evaluation studies | Expert Review of Pharmacoeconomics and Outcomes Research | 2005 | 143 |
22 | Cancer-related fatigue: prevalence, assessment and treatment strategies | Expert Review of Pharmacoeconomics and Outcomes Research | 2011 | 142 |
23 | How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1/3) | Expert Review of Pharmacoeconomics and Outcomes Research | 2016 | 134 |
24 | How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3/3) | Expert Review of Pharmacoeconomics and Outcomes Research | 2016 | 133 |
25 | Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications | Expert Review of Pharmacoeconomics and Outcomes Research | 2010 | 131 |
26 | Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance | Expert Review of Pharmacoeconomics and Outcomes Research | 2009 | 126 |
27 | Priority setting in health: origins, description and application of the Australian Assessing Cost–Effectiveness initiative | Expert Review of Pharmacoeconomics and Outcomes Research | 2008 | 124 |
28 | Direct and indirect cost of managing alzheimer’s disease and related dementias in the United States | Expert Review of Pharmacoeconomics and Outcomes Research | 2017 | 120 |
29 | 3D-printing and the effect on medical costs: a new era? | Expert Review of Pharmacoeconomics and Outcomes Research | 2016 | 115 |
30 | Health-state utility values in breast cancer | Expert Review of Pharmacoeconomics and Outcomes Research | 2010 | 112 |
31 | Quality of life and burden in caregivers for patients with Parkinson’s disease: concepts, assessment and related factors | Expert Review of Pharmacoeconomics and Outcomes Research | 2012 | 112 |
32 | Meta-analysis of rare and adverse event data | Expert Review of Pharmacoeconomics and Outcomes Research | 2002 | 107 |
33 | Economic burden of chronic pain | Expert Review of Pharmacoeconomics and Outcomes Research | 2006 | 106 |
34 | The population-based prescription database IADB.nl: its development, usefulness in outcomes research and challenges | Expert Review of Pharmacoeconomics and Outcomes Research | 2013 | 101 |
35 | Patient preferences and healthcare outcomes: an ecological perspective | Expert Review of Pharmacoeconomics and Outcomes Research | 2012 | 100 |
36 | Conceptual and methodological advances in child-reported outcomes measurement | Expert Review of Pharmacoeconomics and Outcomes Research | 2010 | 99 |
37 | Burden of skin diseases | Expert Review of Pharmacoeconomics and Outcomes Research | 2009 | 96 |
38 | Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT) | Expert Review of Pharmacoeconomics and Outcomes Research | 2018 | 96 |
39 | The EQ-5D-5L Valuation study in Thailand | Expert Review of Pharmacoeconomics and Outcomes Research | 2018 | 94 |
40 | Measuring and managing patient expectations for breast reconstruction: impact on quality of life and patient satisfaction | Expert Review of Pharmacoeconomics and Outcomes Research | 2012 | 93 |
41 | Multiple chronic conditions and healthcare costs among adults | Expert Review of Pharmacoeconomics and Outcomes Research | 2015 | 93 |
42 | Health utility estimation | Expert Review of Pharmacoeconomics and Outcomes Research | 2002 | 91 |
43 | Quantifying stochastic uncertainty and presenting results of cost-effectiveness analyses | Expert Review of Pharmacoeconomics and Outcomes Research | 2001 | 89 |
44 | Quality of life in psoriasis patients | Expert Review of Pharmacoeconomics and Outcomes Research | 2014 | 88 |
45 | Improving the quality of discrete-choice experiments in health: how can we assess validity and reliability? | Expert Review of Pharmacoeconomics and Outcomes Research | 2017 | 88 |
46 | Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG | Expert Review of Pharmacoeconomics and Outcomes Research | 2010 | 83 |
47 | Impact of cardiovascular complications among patients with Type 2 diabetes mellitus: a systematic review | Expert Review of Pharmacoeconomics and Outcomes Research | 2015 | 83 |
48 | Life expectancy and health expenditure evolution in Eastern Europe—DiD and DEA analysis | Expert Review of Pharmacoeconomics and Outcomes Research | 2016 | 81 |
49 | How to prepare a systematic review of economic evaluations for clinical practice guidelines: database selection and search strategy development (part 2/3) | Expert Review of Pharmacoeconomics and Outcomes Research | 2016 | 80 |
50 | Cognitive dysfunction and work productivity in major depressive disorder | Expert Review of Pharmacoeconomics and Outcomes Research | 2016 | 79 |